J. Safra Sarasin Holding AG Decreases Stake in Xenon Pharmaceuticals Inc. $XENE

J. Safra Sarasin Holding AG lowered its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 55.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 13,581 shares of the biopharmaceutical company’s stock after selling 16,587 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Xenon Pharmaceuticals were worth $609,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Wellington Management Group LLP grew its holdings in shares of Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after purchasing an additional 1,435,096 shares during the last quarter. Braidwell LP increased its stake in shares of Xenon Pharmaceuticals by 33.0% in the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock worth $112,837,000 after buying an additional 895,154 shares during the period. Commodore Capital LP raised its holdings in Xenon Pharmaceuticals by 30.1% during the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after buying an additional 700,000 shares during the last quarter. Vestal Point Capital LP raised its holdings in Xenon Pharmaceuticals by 53.8% during the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $62,600,000 after buying an additional 700,000 shares during the last quarter. Finally, Holocene Advisors LP boosted its position in Xenon Pharmaceuticals by 9.2% during the 3rd quarter. Holocene Advisors LP now owns 1,976,553 shares of the biopharmaceutical company’s stock valued at $79,359,000 after buying an additional 167,078 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Analyst Upgrades and Downgrades

XENE has been the topic of a number of recent analyst reports. Stifel Nicolaus set a $66.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, February 10th. Wolfe Research started coverage on shares of Xenon Pharmaceuticals in a research note on Monday, February 23rd. They set an “outperform” rating and a $60.00 price objective for the company. Wedbush dropped their target price on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, March 16th. JPMorgan Chase & Co. raised their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th. Finally, HC Wainwright boosted their price target on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $71.88.

Xenon Pharmaceuticals Stock Up 0.3%

NASDAQ:XENE opened at $56.85 on Friday. The firm’s fifty day simple moving average is $47.69 and its 200 day simple moving average is $43.58. The stock has a market cap of $4.73 billion, a P/E ratio of -13.04 and a beta of 0.74. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period last year, the company posted ($0.84) EPS. On average, analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, insider Christopher John Kenney sold 2,771 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total value of $166,564.81. Following the completion of the sale, the insider directly owned 4,729 shares in the company, valued at $284,260.19. This trade represents a 36.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ian Mortimer sold 270,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $60.33, for a total value of $16,289,100.00. Following the sale, the chief executive officer directly owned 6,000 shares in the company, valued at approximately $361,980. The trade was a 97.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 296,707 shares of company stock worth $17,845,365 over the last 90 days. 4.07% of the stock is owned by company insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.